SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Its lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a stockpile of 1.7 million oral courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox on July 13, 2018. In September 2018, SIGA signed a contract with Biomedical Advanced Research and Development Authority (BARDA) for additional procurement and development related to both oral and intravenous formulations of TPOXX.
Company profile
Ticker
SIGA
Exchange
Website
CEO
Phillip Louis Gomez III
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SIGA PHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
133864870
SIGA stock data
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Results of Operations and Financial Condition
4 May 23
8-K
SIGA Declares Special Cash Dividend of $0.45 Per Share
4 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
10-K
2022 FY
Annual report
2 Mar 23
8-K
Results of Operations and Financial Condition
2 Mar 23
8-K
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023
17 Jan 23
8-K
Departure of Directors or Certain Officers
14 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
Transcripts
SIGA
Earnings call transcript
2023 Q1
4 May 23
SIGA
Earnings call transcript
2022 Q4
2 Mar 23
SIGA
Earnings call transcript
2022 Q3
3 Nov 22
SIGA
Earnings call transcript
2022 Q2
7 Aug 22
SIGA
Earnings call transcript
2022 Q1
8 May 22
SIGA
Earnings call transcript
2021 Q4
4 Mar 22
SIGA
Earnings call transcript
2021 Q3
7 Nov 21
SIGA
Earnings call transcript
2021 Q2
8 Aug 21
SIGA
Earnings call transcript
2021 Q1
9 May 21
SIGA
Earnings call transcript
2020 Q4
4 Mar 21
Latest ownership filings
4
Daniel J Luckshire
12 May 23
4
Dennis E Hruby
12 May 23
SC 13G/A
D. E. SHAW & CO, L.P.
14 Feb 23
4
Jay Varma
14 Nov 22
4
Harold Eugene Jr. Ford
14 Nov 22
3
Jay Varma
14 Nov 22
3
Harold Eugene Jr. Ford
14 Nov 22
SC 13G
D. E. SHAW & CO, L.P.
24 Jun 22
4
Michael C. Plansky
16 Jun 22
4
Holly L. Phillips
16 Jun 22
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 115.68 mm | 115.68 mm | 115.68 mm | 115.68 mm | 115.68 mm | 115.68 mm |
| Cash burn (monthly) | (no burn) | 3.13 mm | 702.77 k | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 6.84 mm | 1.53 mm | n/a | n/a | n/a |
| Cash remaining | n/a | 108.84 mm | 114.15 mm | n/a | n/a | n/a |
| Runway (months of cash) | n/a | 34.8 | 162.4 | n/a | n/a | n/a |
Institutional ownership, Q1 2023
49.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 142 |
| Opened positions | 19 |
| Closed positions | 41 |
| Increased positions | 47 |
| Reduced positions | 46 |
| 13F shares | Current |
|---|---|
| Total value | 177.96 bn |
| Total shares | 35.33 mm |
| Total puts | 94.20 k |
| Total calls | 357.60 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 3.19 mm | $18.37 bn |
| FHI Federated Hermes | 2.81 mm | $16.17 bn |
| Esopus Creek Value Series Fund LP - Series A | 2.37 mm | $21.94 mm |
| Vanguard | 2.25 mm | $12.92 bn |
| Kempen Capital Management | 2.22 mm | $12.79 bn |
| AltraVue Capital | 1.72 mm | $9.92 bn |
| D. E. Shaw & Co | 1.49 mm | $0.00 |
| Jupiter Asset Management | 1.14 mm | $6.54 bn |
| D. E. Shaw & Co. | 1.10 mm | $6.32 bn |
| Dimensional Fund Advisors | 1.06 mm | $6.11 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 11 May 23 | Dennis E Hruby | RSU Common Stock, Par Value $.0001 Per Share | Grant | Acquire A | No | No | 0 | 64,516 | 0.00 | 64,516 |
| 11 May 23 | Daniel J Luckshire | RSU Common Stock, Par Value $.0001 Per Share | Grant | Acquire A | No | No | 0 | 48,387 | 0.00 | 48,387 |
| 10 Nov 22 | Harold Eugene Jr. Ford | Stock Option Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 9.27 | 25,000 | 231.75 k | 25,000 |